Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T16:57:45.845Z.
Calculation as of: 2026-10-06T16:57:45.845Z.
Quote observation: 2026-10-06T16:55:21.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 7a3ccde1bd0df5c55ebc0148063105fff0bf751cb52a3071af3e3331f6001fbe
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Market Cap
$486.60M
EV/EBITDA Ratio
10.48x
TTM Avg
7.79x
3Y Avg
5.90x
5Y Avg
5.85x
Market Cap
$509.10M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$475.60M
EV/EBITDA Ratio
8097.24x
TTM Avg
8683.24x
3Y Avg
8683.24x
5Y Avg
8683.24x
Market Cap
$472.03M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Oculis Holding AG (OCS) | $494.48M | N/A | N/A | N/A | N/A |
| Evolus, Inc. (EOLS)vs › | $490.41M | N/A | N/A | N/A | N/A |
| Puma Biotechnology, Inc. (PBYI)vs › | $486.60M | 10.48x | 7.79x | 5.90x | 5.85x |
| Allogene Therapeutics, Inc. (ALLO)vs › | $509.10M | N/A | N/A | N/A | N/A |
| 908 Devices Inc. (MASS)vs › | $509.56M | N/A | N/A | N/A | N/A |
| Crescent Biopharma, Inc. (CBIO)vs › | $509.80M | N/A | N/A | N/A | N/A |
| Arvinas, Inc. (ARVN)vs › | $478.01M | N/A | N/A | N/A | N/A |
| Cerus Corporation (CERS)vs › | $475.60M | 8097.24x | 8683.24x | 8683.24x | 8683.24x |
| Bright Minds Biosciences Inc. (DRUG)vs › | $472.03M | N/A | N/A | N/A | N/A |
| Altimmune, Inc. (ALT)vs › | $515.36M | N/A | N/A | N/A | N/A |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
